June 16, 2026
NEEDHAM, Mass., June 16, 2026 — Stealth BioTherapeutics Holdings Inc., a commercial-stage biotechnology …
MitoAction in the News
Khondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial Disease
April 16, 2026
NOTES TO EDITORSAbout KhondrionKhondrion is a late-stage clinical biopharmaceutical company focused …
Navigating the FDA’s Complete Response Letter and identifying a path forwardfor SL1009 (DCA).
March 31, 2026
Dear Members of the PDCD Community,
We are deeply grateful for your support and advocacy throughout …
FDA Approval of KYGEVVI Marks a Defining Moment for Mitochondrial Disease Community and Families Affected by TK2d
FOR IMMEDIATE RELEASE
Contact:Emily GrandahlMarketing Coordinator, MitoActionemily@mitoaction.org(888) …
Tisento Therapeutics Announces Publication of MELAS Interview Study, Incorporating Patients’ Perspectives to Elucidate Symptoms and Impacts of Rare Mitochondrial Disease
Originally Published by Tisento Therapeutics on November 3, 2025.
Findings Demonstrate the Importance of Addressing …
- 1
- 2
- 3
- …
- 28
- Next Page »
